Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has issued an announcement.
Simcere Pharmaceutical Group Limited announced the grant of 15,408,100 Restricted Stock Units (RSUs) under its 2021 RSU Scheme to 97 eligible participants, including executive directors and senior management. This grant, which involves shares previously lapsed, is aimed at incentivizing key personnel and aligning their interests with the company’s long-term performance, potentially strengthening its market position.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating within the pharmaceutical industry. It focuses on the development and distribution of pharmaceutical products and services.
Average Trading Volume: 13,647,464
Technical Sentiment Signal: Buy
Current Market Cap: HK$35.41B
For detailed information about 2096 stock, go to TipRanks’ Stock Analysis page.